公开(公告)号：US10941151B2

公开(公告)日：2021-03-09

申请号：US16880337

申请日：2020-05-21

申请人： Ogeda SA

发明人： Hamid R. Hoveyda ,  Guillaume Dutheuil ,  Graeme Lovat Fraser ,  Marie-Odile Roy ,  Mohamed El Bousmaqui ,  Frederic Batt

IPC分类号： C07D241/08 ,  C07D487/04

摘要： The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

公开(公告)号：US20200222399A1

公开(公告)日：2020-07-16

申请号：US16796422

申请日：2020-02-20

申请人： OGEDA SA

发明人： Hamid HOVEYDA ,  Graeme FRASER

IPC分类号： A61K31/4985 ,  A61K31/4725 ,  A61K31/495 ,  A61K31/472 ,  A61P3/04

摘要： Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.

公开(公告)号：US10683295B2

公开(公告)日：2020-06-16

申请号：US16047740

申请日：2018-07-27

申请人： Ogeda SA

发明人： Hamid R. Hoveyda ,  Guillaume Dutheuil ,  Graeme Lovat Fraser ,  Marie-Odile Roy ,  Mohamed El Bousmaqui ,  Frederic Batt

IPC分类号： C07D241/38 ,  C07D487/04

摘要： The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

公开(公告)号：US10214533B2

公开(公告)日：2019-02-26

申请号：US15956311

申请日：2018-04-18

申请人： OGEDA SA

发明人： Hamid Hoveyda ,  Guillaume Dutheuil ,  Graeme Fraser

IPC分类号： C07D487/04 ,  A61K31/4985

摘要： Novel compounds of Formula I and their use in therapeutic treatments.

公开(公告)号：US20180289705A1

公开(公告)日：2018-10-11

申请号：US15557832

申请日：2016-03-16

申请人： OGEDA SA

发明人： Hamid HOVEYDA ,  Graeme FRASER

IPC分类号： A61K31/4985 ,  A61P3/04

摘要： Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.

公开(公告)号：US20180194772A1

公开(公告)日：2018-07-12

申请号：US15906268

申请日：2018-02-27

申请人： Ogeda SA

发明人： Hamid R. Hoveyda ,  Marie-Odile Roy ,  Graeme Lovat Fraser ,  Guillaume Dutheuil

IPC分类号： C07D487/04 ,  A61K31/407 ,  A61K31/4985

CPC分类号： C07D487/04 ,  A61K31/407 ,  A61K31/4985

摘要： The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

公开(公告)号：US20240199618A1

公开(公告)日：2024-06-20

申请号：US18235976

申请日：2023-08-21

申请人： Ogeda SA

发明人： Hamid Hoveyda ,  Guillaume Dutheuil ,  Graeme Fraser

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I




or a pharmaceutically acceptable solvate thereof.

公开(公告)号：US11731974B2

公开(公告)日：2023-08-22

申请号：US17066086

申请日：2020-10-08

申请人： Ogeda SA

发明人： Hamid R. Hoveyda ,  Guillaume Dutheuil ,  Graeme Fraser

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I




or a pharmaceutically acceptable solvate thereof.

公开(公告)号：US11078203B2

公开(公告)日：2021-08-03

申请号：US16629710

申请日：2018-07-12

申请人： OGEDA SA

发明人： Hamid Hoveyda

IPC分类号： C07D487/04 ,  A61P5/08 ,  A61P5/24

摘要： Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.

公开(公告)号：US20200270254A1

公开(公告)日：2020-08-27

申请号：US16629710

申请日：2018-07-12

申请人： OGEDA SA

发明人： Hamid HOVEYDA

IPC分类号： C07D487/04 ,  A61P5/08 ,  A61P5/24

摘要： Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.